• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology: International Journal of Cancer Research and Treatment >Gemcitabine: progress in the treatment of pancreatic cancer.
【24h】

Gemcitabine: progress in the treatment of pancreatic cancer.

机译：吉西他滨：胰腺癌的治疗进展。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor. Treatment with single-agent gemcitabine achieved clinical benefit and symptoms improvement in 20-30% of patients. While 1-year survival was observed in 2% of 5-fluorouracil (5-FU)-treated patients, it was raised to 18% by single-agent gemcitabine. Good treatment tolerability and low incidence of side effects are clear advantages of single-agent gemcitabine. Improvement of efficacy is, however, expected from combination treatment. Gemcitabine and cisplatin given as first-line treatment in three studies achieved a median survival of 7.4-8.3 months. One-year survival was raised to 28% as reported in one study. Comparable activity was obtained by a combination of gemcitabine with 5-FU. Nine studies using gemcitabine in combination with standard-dose or high-dose 5-FU reported a median survival ranging from 5.5 to 13 months. Notwithstanding these promising results, recommendations regarding palliative chemotherapy of pancreatic cancer remain tentative and still need confirmation by presently ongoing phase III trials. Inclusion of pancreatic cancer patients into clinical trials should be a major goal. Outside clinical trials, patients should present with an adequate PS (Karnofsky-performance index greater than or = 70) to qualify for chemotherapy.
机译：不可切除的胰腺癌预后不良，未治疗的患者中位生存期为3-5个月。自从引入吉西他滨以来，胰腺癌可能不再被视为对化疗耐药的肿瘤。用单药吉西他滨治疗可在20-30％的患者中获得临床益处并改善症状。在2％接受5-氟尿嘧啶（5-FU）治疗的患者中观察到1年生存期，而单药吉西他滨将其提高到18％。单药吉西他滨具有明显的优势，即良好的治疗耐受性和较低的副作用发生率。然而，期望通过联合治疗来改善功效。在三项研究中，吉西他滨和顺铂作为一线治疗的中位生存期为7.4-8.3个月。一项研究表明，一年生存率提高到28％。通过吉西他滨与5-FU的组合获得了相当的活性。九项使用吉西他滨与标准剂量或大剂量5-FU联合使用的研究报告中位生存期为5.5至13个月。尽管取得了这些令人鼓舞的结果，但有关胰腺癌姑息化疗的建议仍是暂定的，仍需通过当前正在进行的III期临床试验予以证实。将胰腺癌患者纳入临床试验应该是一个主要目标。除临床试验外，患者应表现出足够的PS（卡诺夫斯基性能指数大于或等于70）以符合化疗的条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号